The head of the U.K.'s Trade & Investment Ministry has begun a three-day visit to India to focus on biotech and health issues, beginning with the Bangalore India Bio, the nation's major biotech conference.
SINGAPORE-- India, Indonesia, Thailand and Vietnam are at the bottom in terms of protections for intellectual property, and much of the rest of Asia is ranked near them in an assessment by a U.S. Chamber of Commerce unit. Singapore was ranked in the top 5 in the Pacific region with Australia, Japan, New Zealand and South Korea close behind.
Setting up camp in the Middle East is the trend du jour in Big Pharma, and Merck KGaA is expanding its footprint there by launching its new diabetes education program in the United Arab Emirates.
India's Cipla argued before the Delhi High Court against the Novartis patent for its Onbrez (indacaterol) COPD drug, saying the patent need not be honored because the Swiss drugmaker was not working it in the country and has licensed it to Lupin instead.
SINGAPORE-- Fujifilm's Toyama Chemical is readying a study for a scientific journal stating that its Avigan (favipiravir) influenza drug has shown promise in treating ebolavirus so far in an early-phase clinical trial in the West African country of Guinea.
SINGAPORE-- Wockhardt's chairman told reporters the company's Illinois production plant, responsible for half its sales in the United States, has taken care of the issues that led the FDA to issue it a Form 483 citing compliance failures last year.
SINGAPORE-- Harbin Gloria Pharmaceuticals will pay RMB 2.39 billion to acquire an 85% stake in Shanxi Powerdone Pharmaceutics, one of two domestic deals in late January involving mainland firms reshuffling biotech assets and traditional Chinese medicines.
SINGAPORE-- Despite missing its target for bringing 15 to 20 drugs to the U.S. market last year, Lupin is optimistic enough about 2015 that it seeks possible acquisitions in Russia to expand its presence there.
The U.S. FDA is hiring new inspectors in India to tackle the high rate of marketing applications made by local firms, an agency official said.
SINGAPORE-- Sometimes it must seem to Pakistan's health authorities they can do nothing right in regulating the nation's pharmaceutical industry.